纳斯达克： -- -- --

最近浏览

实时行情

意见反馈

默沙东

NYSE:MRK 延时15分钟
  • 今开：--
    昨收：--
  • 今日区间：--
    52周区间：--
  • 成交量：--
    成交额：--
  • 市 值：--
    市盈率：--
  • 振幅：
    每股收益：
成交量

董事会

Robert M. Davis
Robert M. Davis is currently Chairman, President & Chief Executive Officer at Merck & Co., Inc. since 2014. He is President, Chief Executive Officer & Director at MSD Pharma (Singapore) Pte Ltd. since 2021. He serves as Chairman & Chief Executive Officer at Merck Sharp & Dohme LLC. He is a Director at Catalyst, Inc., Project HOPE-The-People-To-People Health Foundation, Inc., and AdvaMedDx. He is an Independent Director at Duke Energy Corp. since 2018. He is a Member of the Northwestern University School of Law Board. Former roles include Chairman at Gambro AB, Director at C. R. Bard, Inc. from 2015 to 2017, Director-Corporate Financial Planning at Eli Lilly & Co. from 2002 to 2004, Chief Financial Officer & Vice President at Baxter Healthcare Corp. from 2006 to 2010, VP & President-Medical Products Business at Baxter International, Inc. from 2010 to 2014, and Trustee at Rush University Medical Center. Education includes undergraduate studies at Miami University, an MBA from Kellogg School of Management, and graduate studies at Northwestern University School of Law.
Thomas Henry Glocer
Thomas Henry Glocer founded Angelic Ventures LP in 2012, where he is working as Founding Partner from 2012, Communitas Capital Partners LLC in 2017, where he is working as Partner from 2017, BlueVoyant LLC in 2017, where he is working as Vice Chairman from 2026, and various other companies. Mr. Glocer also currently works at Blueteam Investor LLC, as Chief Executive Officer, Merck & Co., Inc., as Lead Independent Director from 2021, Morgan Stanley, as Lead Independent Director from 2017, and various other companies. Mr. Glocer also formerly worked at Reuters Group Plc, as Chief Executive Officer & Director from 2001 to 2008, Thomson Reuters Plc, as Chief Executive Officer from 2001 to 2009, Thomson Reuters Corp., as Chief Executive Officer & Director from 2008 to 2011, and various other companies. Mr. Glocer received his undergraduate degree in 1981 from The Trustees of Columbia University in The City of New York and graduate degree in 1984 from Yale University.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Patricia Fiorello Russo
Patricia Fiorello Russo is Independent Chairman at Hewlett Packard Enterprise Co. since 2015. Independent Director at Merck & Co., Inc. since 1995. Independent Director at KKR Management LLC since 2011. Lead Independent Director at General Motors Co. since 2021. Independent Director at KKR Group Co., Inc. since 2011. Director at Merck Sharp & Dohme Corp. since 1995. Director at Arconic Defense, Inc. Director at MSD Pharma (Singapore) Pte Ltd. since 1995. Independent Director at KKR & Co., Inc. since 2011. Member of The Conference Board, Inc. Member of The Economic Club of New York. Member of The Business Council. Former roles include Chairman & Chief Executive Officer at Lucent Technologies, Inc. from 2003 to 2006. Chief Executive Officer & Director at Nokia of America Corp. in 2008. Chief Executive Officer at Alcatel Lucent SA from 2006 to 2008. Chairman at Avaya LLC in 2002. Chairman at Partnership for Drug-Free Kids. Lead Independent Director at Arconic, Inc. in 2016. Lead Independent Director at HP, Inc. from 2014 to 2015. Director at Schering-Plough Corp. from 1995 to 2009. Director at Alcoa, Inc. from 1995 to 2009. Director at Arconic Corp. Lead Director at Motors Liquidation Co. Director at Alcoa Corp. Director at DXC Technology Co. Lead Independent Director at Howmet Aerospace, Inc. from 2017 to 2018. President & Chief Operating Officer at Eastman Kodak Co. in 2001. Trustee at Georgetown University. Education includes undergraduate degree from Georgetown University.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Robert M. Davis
Robert M. Davis is currently Chairman, President & Chief Executive Officer at Merck & Co., Inc. since 2014. He is President, Chief Executive Officer & Director at MSD Pharma (Singapore) Pte Ltd. since 2021. He serves as Chairman & Chief Executive Officer at Merck Sharp & Dohme LLC. He is a Director at Catalyst, Inc., Project HOPE-The-People-To-People Health Foundation, Inc., and AdvaMedDx. He is an Independent Director at Duke Energy Corp. since 2018. He is a Member of the Northwestern University School of Law Board. Former roles include Chairman at Gambro AB, Director at C. R. Bard, Inc. from 2015 to 2017, Director-Corporate Financial Planning at Eli Lilly & Co. from 2002 to 2004, Chief Financial Officer & Vice President at Baxter Healthcare Corp. from 2006 to 2010, VP & President-Medical Products Business at Baxter International, Inc. from 2010 to 2014, and Trustee at Rush University Medical Center. Education includes undergraduate studies at Miami University, an MBA from Kellogg School of Management, and graduate studies at Northwestern University School of Law.
Pamela J. Craig
Ms. Pamela J. Craig is an Independent Director at Corning, Inc. and an Independent Director at Merck & Co., Inc. She is on the Board of Directors at Corning, Inc., Progressive Corp., The Committee of 200, Merck & Co., Inc., MSD Pharma (Singapore) Pte Ltd., Comprehensive Development, Inc., Junior Achievement of New Jersey, Inc., Merck Sharp & Dohme Corp. and Smith College. Ms. Craig was previously employed as an Independent Director by 3M Co., an Independent Director by Progressive Insurance, an Independent Director by Wal-Mart Stores, Inc., an Independent Director by VMware, Inc., an Independent Director by Akamai Technologies, Inc., a Chief Financial Officer by Accenture LLP, a Chief Financial Officer by Avanade, Inc., a Chief Financial Officer by Accenture Plc, a Chief Financial Officer by Accenture Ltd., a Chief Financial Officer by Accenture SCA, and a Chairman by C200 Foundation. She received her undergraduate degree from Smith College and an MBA from The Leonard N Stern School of Business.
Paul B. Rothman
Paul B. Rothman is the founder of NexCure LLC. Current jobs include Independent Director at Laboratory Corporation of America Holdings since 2023, Independent Director at Merck & Co., Inc. since 2015, Director at Merck Sharp & Dohme Corp., Director at King Faisal Specialist Hospital & Research Centre, Director at MSD Pharma (Singapore) Pte Ltd. since 2015, Director at Center for Medical Interoperability, Inc. since 2015, Independent Director at Labcorp Holdings, Inc. since 2024, Ex-Officio Trustee at The Johns Hopkins Hospital, Inc., Member of the American Academy of Arts & Sciences, Member of the American Association for the Advancement of Science, Member of the National Academy of Medicine (United States), Member of the Association of American Physicians, Member of the American Society for Clinical Investigation, Trustee at Johns Hopkins Community Physicians, Inc., and Venture Partner at RA Capital Management LP (Private Equity). Former jobs include Chief Executive Officer at Johns Hopkins Medicine, Inc. from 2012 to 2022, Vice Chairman at The Johns Hopkins Health System Corp., Director at Cancer Genetics, Inc. in 2014, Vice President-Medicine at The Johns Hopkins University from 2012 to 2022, and Dean at the University of Iowa Carver College of Medicine from 2008 to 2012. Education includes undergraduate studies at Massachusetts Institute of Technology and a doctorate from Yale University.
Inge G. Thulin
Inge G. Thulin is currently serving as the Vice Chairman at the United States Council for International Business and the Vice Chairman at The Kennedy Center Corporate Fund. He is also an Independent Director at Merck & Co., Inc., a Director at The Council for the United States & Italy, a Director at Merck Sharp & Dohme Corp., a Director at Patricia Industries AB, a Director at MSD Pharma (Singapore) Pte Ltd., and a Member of the Council on Foreign Relations, Inc., The Business Roundtable, The Business Council, The World Economic Forum USA, Inc., The International Business Council, and S llskapet. In his former positions, Mr. Thulin served as the Executive Chairman at 3M Co., an Independent Director at Chevron Corp., an Independent Director at The Toro Co., the Managing Director at 3M Russia ZAO, and held managerial roles at 3M Svenska AB and 3M Europe NV. He was also a Member of Forum Mondial de L'Economie. Mr. Thulin completed his undergraduate degree at the University of Gothenburg.
Mary Ellen Coe
Mary Ellen Coe is currently an Independent Director at Merck & Co., Inc., a Director at Merck Sharp & Dohme Corp., a Director at MSD Pharma (Singapore) Pte Ltd., the President-Global Customer Solutions at Google LLC, and the Chief Business Officer at YouTube, Inc. She previously served as an Independent Director at Whole Foods Market, Inc. Ms. Coe completed her undergraduate degree at the University of Michigan.
Kathy J. Warden
Kathy J. Warden is Chairman, President & Chief Executive Officer at Northrop Grumman Corp. since 2019. Ms. Warden is Chairman at Catalyst, Inc. since 2019. Warden is Vice Chairman at Greater Washington Partnership. Warden is Independent Director at Merck & Co., Inc. since 2020. Warden is Director at Wolf Trap Foundation for the Performing Arts. Warden is Director at Merck Sharp & Dohme Corp. since 2020. Warden is Director at MSD Pharma (Singapore) Pte Ltd. since 2020. Warden is Member of The Business Roundtable. Warden is Member of AFCEA International. Former positions include Vice Chairman at Aerospace Industries Association, Chairman at Federal Reserve Bank of Richmond, Director-Global Services Operating Unit at General Electric Information Services, Senior Manager at GE Aerospace, Senior Vice President at Veridian Corp., President at Northrop Grumman Information Technology, Inc., Vice President & GM-Cyber Intelligence Division at Northrop Grumman Information Technology, Inc., President at Northrop Grumman Mission Systems, Vice President-Intelligence Systems at General Dynamics Advanced Information Systems, Inc., and Member-Visitors Board at James Madison University. Education includes an MBA from George Washington University and an undergraduate degree from James Madison University.
Christine E. Seidman
Christine E. Seidman is the founder of MyoKardia, Inc. (2012). Dr. Seidman is currently an Independent Director at Merck & Co., Inc. (2020), Director-Cardiovascular Genetics Center at The Brigham & Women's Hospital, Inc. (1987), Director at The Burroughs Wellcome Fund, Director at Merck Sharp & Dohme Corp. (2020), Director at MSD Pharma (Singapore) Pte Ltd. (2020), Member of the National Academy of Sciences, Member of the American Academy of Arts & Sciences, Member of the National Academy of Medicine (United States), Member of the American Society for Clinical Investigation, Professor at Harvard Medical School (1997), Member of the Association of University Cardiologists, Scientific Advisory Board at BridgeBio Pharma, Inc., and Venture Partner at Catalio Capital Management LP. Dr. Seidman obtained an undergraduate degree from Harvard University and a doctorate from George Washington University.
Risa J. Lavizzo-Mourey
Currently, Risa J. Lavizzo-Mourey serves as Chairman-Regents Board at the Smithsonian Institution since 2014. Other current roles include Independent Director at Merck & Co., Inc. (since 2020), Director at Princeton Medical Center, Director at Merck Sharp & Dohme Corp., Director at GE Healthcare, Inc. (since 2023), Director at MSD Pharma (Singapore) Pte Ltd. (since 2020), Independent Director at Better Therapeutics LLC (since 2021), Trustee at Howard Hughes Medical Institute, Inc. (since 2021), Member of the National Academy of Sciences, American Philosophical Society, American Academy of Arts & Sciences, and National Academy of Medicine (United States), and Board of Advisors at Healthquest Capital Management Co LLC (since 2022). Former positions include President Emerita & CEO of The Robert Wood Johnson Foundation; Co-Chairman of White House Health Care & Rehabilitation Center, Inc. (1985–1998);. Independent Director at Hess Corp. (2004–2020); Independent Director at GE Aerospace (2017–2023); Director at Hanger, Inc.; Director at Beckman Coulter, Inc. (2001–2007); Independent Director at Genworth Financial, Inc. (2007–2012); Lead Independent Director at GE Healthcare Technologies, Inc. (2023–2026); Director at Independent Sector; Director at Institute on Aging (1994–2002); Independent Director at Better Therapeutics, Inc. (2021–2024); Independent Director at Intel Corp. (2018–2025); Trustee at Penn Medicine Princeton Health; Deputy Administrator at Agency for Healthcare Research & Quality (1992–1994); Principal at Perelman School of Medicine (1986–1992); Professor at the University of Pennsylvania Medical Center (1995–2001). Education includes undergraduate studies at Stony Brook University, a doctorate from Harvard Medical School conferred in 1979, and an MBA from The Wharton School of the University of Pennsylvania conferred in 1986.
Stephen L. Mayo
Stephen L. Mayo is the founder of Xencor, Inc. (1997). Dr. Mayo is also the founder of Molecular Simulations, Inc.,Protabit LLC. Current jobs include Independent Director at Merck & Co., Inc. since 2021, Independent Director at Sarepta Therapeutics, Inc. since 2021, Director at MSD Pharma (Singapore) Pte Ltd. since 2021, Independent Director at Allogene Therapeutics, Inc. since 2022, and Professor at California Institute of Technology since 2020. Former jobs include Director at American Association for the Advancement of Science from 2010 to 2014 and Director at The National Science Foundation from 2013 to 2018. Education includes a doctorate from California Institute of Technology (1987) and an undergraduate degree from The Pennsylvania State University (1983).
Douglas M. Baker
Mr. Douglas M. Baker, Jr., is a Founding Partner at E2SG Partners LP, an Independent Director at Merck & Co., Inc., an Independent Director at Target Corp., a Chairman at ChampionX Holding, Inc. and a Member at Chief Executives For Corporate Purpose, Inc. He is on the Board of Directors at Merck & Co., Inc., Mayo Clinic, Target Corp., Minneapolis Saint Paul Regional Economic Development Partners, Minnesota Orchestral Association, Parent Aware For School Readiness, College of the Holy Cross (Massachusetts) and National Restaurant Association Educational Foundation. Mr. Baker was previously employed as an Independent Director by U.S. Bancorp and an Executive Chairman by Ecolab, Inc. He also served on the board at Nalco Holding Co. He received his undergraduate degree from the College of the Holy Cross (Massachusetts).
Surendralal Lanca Karsanbhai
Surendralal Lanca Karsanbhai currently works at Emerson Electric Co., as President, Chief Executive Officer & Director from 2021, Federal Reserve Bank of St. Louis, as Deputy Chairman, US-China Business Council, as Director, Merck & Co., Inc., as Director from 2025, The Business Roundtable, as Member, and Olin Business School, as Member. Mr. Karsanbhai received his graduate degree from Washington University in St. Louis and undergraduate degree from the University of Michigan.